Is Eye Cancer Curable? What the Evidence Shows for Each Type

Is eye cancer curable? For many people, yes. Most eye cancers can be controlled in the eye, and a large proportion are cured — especially when they are found while still small. But "eye cancer" covers very different diseases, from melanoma inside the eye in adults to retinoblastoma in young children and skin cancers of the eyelid, and each has its own outlook.

This article explains what "cure" and "control" mean, the published outcomes for the main types, and why early diagnosis matters.

Is eye cancer curable? The outlook at a glance

These figures describe large groups of patients and cannot predict one person's outcome, which depends on the tumor's type, size, location and genetics.

What do "cure" and "control" mean?

• Local control means the tumor in the eye has been destroyed or has stopped growing. After modern radiotherapy for uveal melanoma, this is achieved in about 95% of eyes.
• Cure means the cancer is gone and does not return anywhere in the body. Because some cancers come back years later, results are usually reported as survival at 5 or 10 years.
• Remission, a term used mostly for lymphoma, means no detectable disease after treatment.

These goals can come apart: a melanoma can be controlled in the eye even though cells had spread before treatment. For children with retinoblastoma, the goals come in a fixed order — first the child's life, then the eye, then as much vision as possible.

Can you survive uveal melanoma (eye melanoma)?

Yes — most people do. In the United States, about 84% of people with melanoma of the eye are alive five years after diagnosis: 88% when the cancer is confined to the eye, 65% when it has reached nearby tissue and 19% when it has spread to distant organs (American Cancer Society, cases from 2015–2021).

Treating the tumor in the eye is usually successful, and for medium-sized tumors the Collaborative Ocular Melanoma Study found no difference in survival between eye-preserving plaque brachytherapy and removal of the eye. The main risk is metastasis — spread through the bloodstream, most often to the liver — which develops in roughly a quarter of patients within five years and about a third within ten. It depends strongly on tumor thickness:

Genetic testing of tumor cells refines the estimate: with gene-expression profiling, the 5-year risk of metastasis is about 2% for Class 1A tumors, 21% for Class 1B and 72% for Class 2 (see genetic testing and biopsy). Iris melanoma, at the front of the eye, has a much better outlook, with 5-year survival above 95%.

If melanoma spreads, treatment aims to control it: tebentafusp, approved for the tissue type HLA-A*02:01, doubled 5-year survival in its phase 3 trial compared with other treatments (16% versus 8%). See uveal melanoma prognosis and metastasis and follow-up.

Is retinoblastoma curable?

Retinoblastoma, the eye cancer of young children, is highly curable when diagnosed in time. A study of 4,064 children from 149 countries found 3-year survival of 99.5% in high-income countries, 91.2% in upper-middle-income, 80.3% in lower-middle-income and 57.3% in low-income countries. The gap is driven largely by late diagnosis: 42.9% of children in low-income countries already had cancer outside the eye at diagnosis, compared with 0.8% in high-income countries.

Many eyes are now saved with chemotherapy delivered into the eye's artery or into the eye, combined with laser and freezing treatment; very advanced eyes may still need removal to protect the child's life (see retinoblastoma).

Are cancers of the eye surface and eyelid curable?

Usually, yes — and they tend to be visible early:

• Ocular surface squamous neoplasia, ranging from precancerous change to squamous cell carcinoma of the conjunctiva and cornea, is usually curable with surgery or chemotherapy eye drops. In a large series it recurred in about 10% within one year and 17–21% within five years after surgery, so follow-up is long-term (see OSSN).
• Conjunctival melanoma behaves more like skin melanoma and can spread to lymph nodes. In population data, about 83% of patients had not died of melanoma five years after diagnosis, and 69% at ten years; local recurrence is common, so lifelong check-ups are advised.
• Basal cell carcinoma, about 8–9 of every 10 eyelid cancers, almost never spreads; complete removal with margin control cures up to about 98% at five years. Rarer types need wider surgery and closer follow-up (see eyelid cancer).

Is lymphoma of the eye curable?

Lymphoma around the eye — in the conjunctiva, eyelid, orbit or tear gland — is usually a slow-growing type, extranodal marginal zone (MALT) lymphoma. In a large series of conjunctival lymphomas, 5-year lymphoma-specific survival for this type was 97%; rarer, faster-growing types have a less favorable outlook. Lymphoma inside the eye (vitreoretinal lymphoma) usually responds to treatment in the eye, but it is linked to lymphoma of the brain, which largely determines the outlook (see intraocular lymphoma).

Why do early diagnosis and follow-up matter so much?

Across almost every type of eye cancer, smaller tumors found earlier are easier to treat, more often allow the eye and sight to be kept, and spread less often. In uveal melanoma, metastasis risk rises with thickness — which is why a suspicious choroidal nevus is photographed and measured regularly. In retinoblastoma, survival depends above all on how early the diagnosis is made.

Follow-up matters because some cancers return late. For uveal melanoma, the 2026 NCCN guidelines recommend liver imaging for 5 to 10 years, from every 3–6 months to once a year depending on the tumor's risk, so that any problem is found while it is still treatable.